In late 2023, trillion-dollar chipmaker and high-end graphics processing unit (GPU) manufacturer Nvidia joined forces with Recursion, one of the few AI biotech companies that have assets in Phase 2 or Phase 3 trials, to accelerate foundational models in biology and chemistry at an unprecedented scale in the biopharma space.

This collaboration, along with others, exemplifies the growing “techbio” industry, which leverages technology to expedite drug discovery. As Kimberly Powell, head of Nvidia’s healthcare segment, aptly shared in a Bloomberg report, data can “drive what biology they’re going after, instead of the biology influencing what technology they need to use,” emphasizing the synergy between the two fields.

BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico. The company will present four posters showcasing these research collaborations and provide updates on other internal research activities at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, Calif.

Oak Ridge National Laboratory’s Frontier, the world’s first exascale supercomputer with its dizzying 1.1 exaflop speed, is a game-changer for scientific domains ranging from drug discovery to material science and oceanography.

Lincoln Property Company (“Lincoln”), Cresa Boston, and BPGbio, Inc, a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that BPGbio has leased approx. 70,000 sq. ft. of lab and office space at 300 Third Avenue in Waltham, Mass. The company plans to relocate its headquarters from Framingham and expand into two full floors of the new space circa June 2025, significantly increasing its footprint in the Boston region.

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the appointment of Ritesh Srivastava as General Counsel. In this role, Mr. Srivastava will lead legal and compliance functions for the company as it grows its therapeutics and diagnostics businesses through R&D and new development and commercial partnerships. 

In an AI hype-filled biopharma industry, one company is taking a back-to-basics yet supercomputer-powered approach — using Bayesian analysis on massive patient datasets to guide drug discovery.